First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

1. Reck, M.
2. Ciuleanu, T.-E.
3. Cobo, M.
4. Schenker, M.
5. Zurawski, B.
6. Menezes, J.
7. Richardet, E.
8. Bennouna, J.
9. Felip, E.
10. Juan-Vidal, O.
11. Alexandru, A.
12. Cheng, Y.
13. Sakai, H.
14. Paz-Ares, L.
15. Lu, S.
16. John, T.
17. Sun, X.
18. Moisei, A.
19. Taylor, F.
20. Lawrance, R.
21. Zhang, X.
22. Sylvester, J.
23. Yuan, Y.
24. Blum, S.I.
25. Penrod, J.R.
26. Carbone, D.P.
27. Alle Autoren anzeigen +